Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Reduced-Intensity Stem Cell Conditioning

Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors

Leukemia volume 22, pages 31–41 (2008)Cite this article

Abstract

The optimal donor for a patient undergoing reduced-intensity stem cell transplantation remains a human leukocyte antigen (HLA)-matched relative. Alternative donors such as matched unrelated donors (MUDs), mismatched related donors (haploidentical), or unrelated umbilical cord blood (UCB) units have emerged as options as well. The most experience thus far has been with MUD donors, mostly attributed to the development of allele-specific DNA-based HLA-typing methods. The biggest drawback remains the significant delay needed to locate a donor. Haploidentical donors exist for almost all patients, and offer the convenience of a living related donor. However, significant rates of graft-versus-host disease (GVHD) and other toxicities continue to complicate such HLA mismatching. UCB is the most recent option for source of stem cells. Frozen cord blood units can be acquired almost immediately and are able to safely traverse 1 or 2-HLA antigen mismatch barriers. The experience with UCB has been limited by the low cell dose, although recent innovations are attempting to overcome this. In this review, we summarize the current experience and knowledge with alternative donors as stem cell sources for reduced-intensity transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Georges GE, Storb R, Thompson JD, Yu C, Gooley T, Bruno B et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000; 95: 3262–3269.

    CAS  Google Scholar 

  2. Mapara MY, Pelot M, Zhao G, Swenson K, Pearson D, Sykes M . Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant 2001; 7: 646–655.

    Article  CAS  Google Scholar 

  3. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG et al. Lymphohematopoietic graft-vs. host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133–143.

    Article  CAS  Google Scholar 

  4. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309–320.

    Article  CAS  Google Scholar 

  5. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047–1055.

    Article  Google Scholar 

  6. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–1814.

    Article  CAS  Google Scholar 

  7. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1326–1334.

    Article  Google Scholar 

  8. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128–135.

    Article  CAS  Google Scholar 

  9. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322–328.

    Article  CAS  Google Scholar 

  10. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601–607.

    Article  Google Scholar 

  11. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695–5702.

    Article  Google Scholar 

  12. Cao TM, Tsai S, Kelley L, Alder SC, Fuller TC, Pulsipher M . Comparable survival and transplant-related mortality following allogeneic hematopoietic cell transplantation from HLA allele-matched unrelated and HLA-identical sibling donors. Blood 2006; 108: Abstract 3146.

  13. Sobecks R, Ball EJ, Rybicki L, Kuczkowski E, Kalaycio M, Pohlman B et al. Improved outcomes with class I and II DNA-based HLA typing for matched unrelated donor (MUD) allogeneic bone marrow transplant (ABMT) in hematologic diseases. Blood 2004; 104: Abstract 5181.

  14. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108–3114.

    CAS  Google Scholar 

  15. Filion A, Loiseau P, Rocha V, Tamouza R, Chevret S, Busson M et al. Decreased transplant related mortality and better survival in HLA matched (12/12 A, B, C, DRB1, DQB1, DPB1) unrelated bone marrow transplants. Blood 2004; 104: Abstract 977.

  16. Toma A, Balere-Appert ML, Chir Z, Boiron JM, Bordigoni P, Socie G et al. Impact of HLA Allele mismatch on the outcome of patients with reduced-intensity allogeneic haematopoietic stem cell transplantation from unrelated donors: analysis of 103 patients of the French registry. Blood 2006; 108: Abstract 3149.

  17. Mielcarek M, Storer B, Kahl C, Sandmaier BM, Maloney D, Maris M et al. Nonmyeloablative and myeloablative hematopoietic cell transplantation for hematologic malignancies: outcomes with HLA-matched unrelated donors compared to HLA-identical sibling donors. Blood 2005; 106: Abstract 658.

  18. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  Google Scholar 

  19. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021–2030.

    Article  CAS  Google Scholar 

  20. Maris M, Sandmaier BM, Storer B, Shizuru JA, Maloney D, Agura E et al. Unrelated donor peripheral blood stem cell (PBSC) transplantation using nonmyeloablative conditioning and mycophenolate mofetil (MMF) TID results in high engraftment rates. Blood 2004; 104: Abstract 1818.

  21. Baron F, Maris M, Storek J, Metcalf M, White K, Sandmaier BM et al. Immunologic recovery after nonmyeloablative (NM) conditioning: A comparison between related versus unrelated donor hematopoietic cell transplantation (HCT). Blood 2005; 106: Abstract 1402.

  22. Wang Z, Schoch G, Leisenring WM, Sandmaier BM, Maloney D, Storb R . Platelet and red blood cell (RBC) transfusion requirements of nonmyeloablative (NM) HLA-matched related and unrelated donor hematopoietic cell transplantation (HCT): influence of genetic disparity and ABO-incompatibility. Blood 2006; 108: Abstract 2985.

  23. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    Article  CAS  Google Scholar 

  24. Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006; 82: 913–919.

    Article  Google Scholar 

  25. Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant 2004; 33: 697–702.

    Article  CAS  Google Scholar 

  26. Kim SW, Hino M, Hatanaka K, Ueda Y, Tanosaki R, Hirokawa M et al. Reduced intensity conditioning (RIC) with Cladribine, Busulfan and 4 Gy total body irradiation (TBI) for bone marrow transplantation (BMT) from an HLA-matched unrelated donor (URD): a prospective multi-institutional clinical trial. Blood 2006; 108: Abstract 5397.

  27. Bosi A, Bacigalupo A, Soligo D, Fanin R, Lamparelli T, Benedetti F et al. Unrelated hematopoietic stem cell transplantation with reduced intensity regimens in high risk patients for age or disease: results from two independent prospective GITMO studies. Blood 2005; 106: Abstract 2888.

  28. Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 272–279.

    Article  Google Scholar 

  29. Michallet M, Prebet T, Le QH, Michallet AS, Van Biezen A, Brand R et al. Transplant outcome of unrelated hematopoietic stem cell transplantation (HSCT) after myelo-ablative or reduced intensity conditioning (RIC) for chronic lymphocytic leukemia (CLL) a study of EBMT registry. Blood 2005; 106: Abstract 561.

  30. Kroeger N, Brand R, Martino R, Guardiola P, van Biezen A, Zander A et al. Allogeneic stem cell transplantation from unrelated donors after reduced intensity conditioning in patients with MDS/sAML. A report from the chronic leukemia working party (CLWP) of the EBMT. Blood 2004; 104: Abstract 5176.

  31. Lim ZY, Ho A, Kenyon M, Devereux S, Duarte R, Pagliuca A et al. Reduced intensity conditioned volunteer unrelated donor transplants using alemtuzumab are safe and effective in older patients with myelodysplastic syndromes. Blood 2005; 106: Abstract 444.

  32. Devetten MP, Parameswaran H, Carerras J, Logan BR, van Besien K, Vose JM et al. Unrelated donor nonmyeloablative/reduced intensity (NST/RIC) hematopoietic stem cell transplantation (HCT) for patients with relapsed and refractory Hodgkin's lymphoma (HL). Blood 2006; 108: Abstract 601.

  33. Anderlini P, Saliba RM, Acholonu S, Giralt S, Khouri I, Andersson B et al. Two-year follow-up results at the M.D. Anderson Hospital with reduced-intensity allogeneic stem cell transplantation with fludarabine–melphalan as preparative regimen in relapsed/refractory Hodgkin's lymphoma: comparable outcome with matched related and unrelated donors. Blood 2006; 108: Abstract 3115.

  34. Georges GE, Maris M, Maloney D, Sandmaier BM, Sorror ML, Shizuru JA et al. Nonmyeloablative unrelated donor (URD) hematopoietic cell transplantation (HCT) for the treatment of patients (pts) with poor-risk, relapsed or refractory multiple myeloma. Blood 2005; 106: Abstract 2893.

  35. Mytilineos J, Hirv K . HLA-DRB I allele and DRB I-DQB 1 haplotype frequency as prediction criterion for the duration of an unrelated blood stem cell donor search. Biol Blood Marrow Transplant 2007; 13 (Suppl 2): Abstract 339.

  36. Ho VT, Dranoff G, Kim HT, Pasek M, Cutler C, Koreth J et al. GM-CSF secreting leukemia cell vaccinations after allogeneic reduced-intensity peripheral blood stem cell transplantation (SCT) for advanced myelodysplastic syndrome (MDS) or refractory acute myeloid leukemia (AML). Biol Blood Marrow Transplant 2007; 13 (Suppl 2): Abstract 59.

  37. Kato K, Khaled Y, Braun T, Levine JE, Ferrara JL, Mineishi S et al. Superior disease-free survival in acute myelogenous leukemia/myelodysplastic syndrome receiving reduced-intensity allogeneic hematopoietic stem cell transplantation from unrelated donors using fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant 2007; 13 (Suppl 2): Abstract 361.

  38. Spitzer TR . Haploidentical stem cell transplantation: the always present but overlooked donor. Hematol Am Soc Hematol Educ Program 2005, 390–395.

    Article  Google Scholar 

  39. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–771.

    Article  CAS  Google Scholar 

  40. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612–615.

    Article  CAS  Google Scholar 

  41. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.

    Article  CAS  Google Scholar 

  42. Dey BR, Spitzer TR . Current status of haploidentical stem cell transplantation. Br J Haematol 2006; 135: 423–437.

    Article  Google Scholar 

  43. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M . Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903–1909.

    Article  CAS  Google Scholar 

  44. Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75: 1748–1751.

    Article  CAS  Google Scholar 

  45. Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128: 351–359.

    Article  CAS  Google Scholar 

  46. Levy MY, Symons HJ, Fuchs EJ . Clinical tumor responses despite graft rejection after nonmyeloablative conditioning and transplantation of partially HLA-mismatched (haploidentical) bone marrow. Blood 2005; 106: Abstract 2897.

  47. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–386.

    Article  Google Scholar 

  48. Fuchs EJ, Lunzik L, Chen AR, Phelps M, Crawford A, Brodsky RA et al. Post-transplantation cyclophosphamide (Cy) reduces graft rejection and graft-versus-host disease (GVHD) after non-myeloablative, partially HLA-mismatched (haploidentical) bone marrow transplantation (BMT). Blood 2004; 104: 437a.

    Google Scholar 

  49. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690–697.

    Article  CAS  Google Scholar 

  50. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–1084.

    Article  Google Scholar 

  51. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814–819.

    Article  CAS  Google Scholar 

  52. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  Google Scholar 

  53. Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G . Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004; 103: 2860–2861; author reply 2862.

    Article  Google Scholar 

  54. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825–3827.

    Article  CAS  Google Scholar 

  55. Ruggeri L . Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; In: press.

    Google Scholar 

  56. Symons HJ, Leffell MS, Rossiter ND, Sugar E, Luznik L, Phelps M et al. Impact of killer immunoglobulin receptor (KIR) ligand incompatibility in nonmyeloablative bone marrow transplantation (BMT) from haploidentical donors. Blood 2006; 108: Abstract 604.

  57. van Rood JJ, Loberiza Jr FR, Zhang MJ, Oudshoorn M, Claas F, Cairo MS et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99: 1572–1577.

    Article  Google Scholar 

  58. Ichinohe T, Uchiyama T, Shimazaki C, Matsuo K, Tamaki S, Hino M et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 2004; 104: 3821–3828.

    Article  CAS  Google Scholar 

  59. Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y . Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant 2004; 34: 897–899.

    Article  CAS  Google Scholar 

  60. Shimazaki C, Fuchida S, Ochiai N, Nakano S, Yamada N, Uchida R et al. Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism. Br J Haematol 2004; 127: 474–475.

    Article  Google Scholar 

  61. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J . Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 2006; 38: 83–93.

    Article  CAS  Google Scholar 

  62. Ballen KK . New trends in umbilical cord blood transplantation. Blood 2005; 105: 3786–3792.

    Article  CAS  Google Scholar 

  63. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–2275.

    Article  CAS  Google Scholar 

  64. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.

    Article  CAS  Google Scholar 

  65. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813–3820.

    Article  CAS  Google Scholar 

  66. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343–1347.

    Article  CAS  Google Scholar 

  67. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood 2003; 101: 5061–5067.

    Article  CAS  Google Scholar 

  68. Fernandez MN, Regidor C, Cabrera R, Garcia-Marco JA, Fores R, Sanjuan I et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol 2003; 31: 535–544.

    Article  Google Scholar 

  69. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82–89.

    Article  CAS  Google Scholar 

  70. Cutler C, Li S, Ho V, Koreth J, Alyea E, Soiffer R et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Biol Blood Marrow Transplant 2007; 13: 122 (abstract 337).

    Article  Google Scholar 

  71. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE . Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102: 1915–1919.

    Article  CAS  Google Scholar 

  72. Brunstein CG, Barker JN, Weisdorf DJ, DeFor T, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007, published online June 14, 2007.

  73. Rio B, Belhocine R, Renaud M, Francois S, Gluckman E, Blaise D et al. Reduced intensity conditioning regimen for unrelated cord blood transplantation in adults. A multicentric phase I–II trial. Blood 2005; 106: 3658 (abstract).

    Article  Google Scholar 

  74. Chao NJ, Koh LP, Long GD, Gasparetto C, Horwitz M, Morris A et al. Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biol Blood Marrow Transplant 2004; 10: 569–575.

    Article  Google Scholar 

  75. Horwitz M, Rizzieri DA, Long GD, Gasparetto C, Morris A, Sullivan KM et al. Adult umbilical cord blood transplantation following non-myeloablative conditioning; impact of increased cell dose and 200 cGy TBI on engraftment and survival. Blood 2006; 108: 5399 (abstract).

    Google Scholar 

  76. Miyakoshi S, Yuji K, Kusumi E, Kato D, Koyama S, Fujiwara M et al. Reduced-intensity unrelated cord blood transplantation (RICBT) for adults with hematological diseases. Blood 2004; 104: 2763 (abstract).

    Google Scholar 

  77. Hamaki T, Kajiwara K, Hoshi K, Kogure K, Harima A, Yamada K et al. Reduced intensity cord blood transplantation using mycophenolate mofetil and cyclosporine for adult patients with advanced hematologic malignancies. Blood 2005; 106: 2889 (abstract).

    Google Scholar 

  78. Yuji K, Miyakoshi S, Takagi S, Kato D, Miura Y, Narimatsu H et al. Reduced-intensity unrelated cord-blood transplantation (RI-UCBT) for patients with high-risk myeloid malignancies. Blood 2005; 106: 2891 (abstract).

    Google Scholar 

  79. Morii T, Amano I, Tanaka H, Takahashi T, Kimura H . Reduced-Intensity unrelated cord blood transplantation (RICBT) in adult patients with high-risk hematological malignancies. Blood 2005; 106: 5433 (abstract).

    Google Scholar 

  80. Komatsu T, Narimatsu H, Yoshimi A, Kurita N, Kusakabe M, Hori A et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol 2007; 86: 49–54.

    Article  CAS  Google Scholar 

  81. Yamamoto H, Uchida N, Matsumura T, Takagi S, Kato D, Matsuhashi Y et al. High incidence of cytomegalovirus reactivation and diseases following reduced-intensity cord blood transplantation for adult patients. Blood 2006; 108: 2846 (abstract).

    Article  Google Scholar 

  82. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874–2880.

    Article  CAS  Google Scholar 

  83. Marty F, Ho VT, Seeley WW, Cutler C, Koreth J, Alyea E et al. Risk of HHV6-associated post-transplant acute limbic encephalitis (PALE) after umbilical cord blood stem cell transplantation: A cohort analysis. Blood 2006; 108: 2929 (abstract).

    Google Scholar 

  84. Chen SF, DeFor T, Thomas AJ, Baker KS . Double umbilical cord blood transplant patients have a higher risk of HHV-6 infection. Blood 2006; 108: 5305 (abstract).

    Google Scholar 

  85. MacMillan M, Brunstein CG, DeFor T, Blazar BR, Weisdorf DJ, Wagner J . Single versus double umbilical cord blood transplantation (UCBT): higher risk of acute graft-versus-host disease (GVHD) but lower transplant related mortality (TRM) in recipients of double UCBT. Blood 2006; 108: 435 (abstract).

    Google Scholar 

  86. Verneris MR, Brunstein CG, DeFor T, Barker JN, Weisdorf DJ, Blazar BR et al. Risk of relapse (REL) after umbilical cord blood transplantation (UCBT) in patients with acute leukemia: marked reduction in recipients of two units. Blood 2005; 106: abstract 305.

  87. Barker JN, Scaradavou A, Stevens C, Rubinstein P . Analysis of 608 umbilical cord blood (UCB) transplants: HLA-match is a critical determinant of transplant-related mortality (TRM) in the post-engraftment period even in the absence of acute graft-vs-host disease (aGVHD). Blood 2005; 106: 303 (abstract).

    Google Scholar 

  88. Matsuno N, Wake A, Uchida N, Takagi S, Kato D, Matsuhashi Y et al. Impact of human leukocyte antigen compatibility on engraftment in adult patients receiving reduced-intensity umbilical cord blood transplantation using calcineurin inhibitor alone for GVHD prophylaxis. Blood 2006; 108: 3147 (abstract).

    Google Scholar 

  89. Tashiro H, Kozai Y, Goto M, Noguchi M, Shiraski R, Kawasugi K et al. Comparison of adult allogeneic umbilical cord blood transplantation between myeloablative and non-myeloablative conditioning regimens. Biol Blood Marrow Transplant 2005; 11: 929 (abstract 925).

    Article  Google Scholar 

  90. Brunstein CG, Setubal D, Tomblyn M, DeFor T, Arora M, Burns LJ et al. Umbilical cord blood transplant after reduced intensity conditioning provides outcomes comparable HLA-matched siblings for patients with high risk and advanced acute myeloid leukemia. Blood 2006; 108: Abstract 606.

  91. Miyakoshi S, Yuji K, Kusumi E, Kato D, Takagi S, Uchida N et al. Comparison among related peripheral blood stem cell transplantation (R-PBSCT), unrelated bone marrow transplantation (U-BMT), and Unrelated cord blood transplantation (U-CBT) with reduced intensity regimens for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 2005; 106: 5441 (abstract).

    Google Scholar 

  92. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ . Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107: 3804–3807.

    Article  CAS  Google Scholar 

  93. Shaw BE, Russell NH, Devereux S, Emma DG, Stephen M, Madrigal JA et al. Single HLA allele mismatches are well tolerated in the recipients of T cell depleted reduced intensity conditioned transplants from unrelated donors. Blood 2005; 106: Abstract 2895.

Download references

Author information

Authors and Affiliations

  1. Division of Bone Marrow Transplantation, Hematology/Oncology Unit, Massachusetts General Hospital, Boston, MA, USA

    Y-B Chen & T R Spitzer

Authors
  1. Y-B Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T R Spitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T R Spitzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, YB., Spitzer, T. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia 22, 31–41 (2008). https://doi.org/10.1038/sj.leu.2404932

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404932

Keywords

This article is cited by

Search

Advanced search

Quick links